Charles Schwab’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-15,686
| Closed | -$91.6K | – | 3618 |
|
|
2022
Q4 | $91.6K | Hold |
15,686
| – | – | ﹤0.01% | 3272 |
|
|
2022
Q3 | $106K | Buy |
+15,686
| New | +$95.1K | ﹤0.01% | 3219 |
|
|
2022
Q2 | – | Sell |
-23,681
| Closed | -$80K | – | 3698 |
|
|
2022
Q1 | $80K | Buy |
+23,681
| New | +$75.1K | ﹤0.01% | 3454 |
|
|
2021
Q3 | – | Sell |
-10,357
| Closed | -$44K | – | 3566 |
|
|
2021
Q2 | $44K | Sell |
10,357
-65,111
| -86% | -$276K | ﹤0.01% | 3388 |
|
|
2021
Q1 | $377K | Buy |
75,468
+3,500
| +5% | +$28.3K | ﹤0.01% | 3175 |
|
|
2020
Q4 | $910K | Buy |
71,968
+2,143
| +3% | +$24.4K | ﹤0.01% | 2807 |
|
|
2020
Q3 | $686K | Sell |
69,825
-2,173
| -3% | -$21.4K | ﹤0.01% | 2790 |
|
|
2020
Q2 | $717K | Buy |
71,998
+4,873
| +7% | +$46.7K | ﹤0.01% | 2720 |
|
|
2020
Q1 | $594K | Buy |
67,125
+15,823
| +31% | +$156K | ﹤0.01% | 2655 |
|
|
2019
Q4 | $474K | Buy |
51,302
+2,475
| +5% | +$17.5K | ﹤0.01% | 2832 |
|
|
2019
Q3 | $288K | Hold |
48,827
| – | – | ﹤0.01% | 2977 |
|
|
2019
Q2 | $586K | Buy |
48,827
+2,658
| +6% | +$28.6K | ﹤0.01% | 2741 |
|
|
2019
Q1 | $558K | Buy |
46,169
+1,529
| +3% | +$22.5K | ﹤0.01% | 2725 |
|
|
2018
Q4 | $561K | Sell |
44,640
-50,547
| -53% | -$698K | ﹤0.01% | 2722 |
|
|
2018
Q3 | $1.41M | Hold |
95,187
| – | – | ﹤0.01% | 2523 |
|
|
2018
Q2 | $1.6M | Buy |
95,187
+7,500
| +9% | +$146K | ﹤0.01% | 2436 |
|
|
2018
Q1 | $2.01M | Buy |
87,687
+51,066
| +139% | +$1.14M | ﹤0.01% | 2331 |
|
|
2017
Q4 | $948K | Buy |
36,621
+4,499
| +14% | +$90.6K | ﹤0.01% | 2520 |
|
|
2017
Q3 | $474K | Hold |
32,122
| – | – | ﹤0.01% | 2733 |
|
|
2017
Q2 | $449K | Buy |
32,122
+10,400
| +48% | +$153K | ﹤0.01% | 2727 |
|
|
2017
Q1 | $371K | Hold |
21,722
| – | – | ﹤0.01% | 2751 |
|
|
2016
Q4 | $224K | Hold |
21,722
| – | – | ﹤0.01% | 2938 |
|
|
2016
Q3 | $220K | Sell |
21,722
-17,504
| -45% | -$191K | ﹤0.01% | 2898 |
|
|
2016
Q2 | $441K | Hold |
39,226
| – | – | ﹤0.01% | 2633 |
|
|
2016
Q1 | $536K | Buy |
39,226
+9,547
| +32% | +$137K | ﹤0.01% | 2553 |
|
|
2015
Q4 | $564K | Hold |
29,679
| – | – | ﹤0.01% | 2604 |
|
|
2015
Q3 | $558K | Buy |
29,679
+7,957
| +37% | +$135K | ﹤0.01% | 2582 |
|
|
2015
Q2 | $324K | Buy |
+21,722
| New | +$331K | ﹤0.01% | 2840 |
|
Charles Schwab's CNCE Position: Q1 2023 in Review
Charles Schwab sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 15,686 shares — an estimated $91.6K sold.
Charles Schwab first reported a position in CNCE in Q2 2015 and held it in 28 quarters. The position peaked at $2.01M in Q1 2018. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.
- Charles Schwab reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- Charles Schwab sold 15,686 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $91.6K.
- Charles Schwab first reported a position in Concert Pharmaceuticals, Inc. in Q2 2015 and held it in 28 quarters.
- Charles Schwab's Concert Pharmaceuticals, Inc. position peaked at $2.01M in Q1 2018.
- 0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.
Based on Charles Schwab's 13F filing for Q1 2023, filed 12 May 2023.